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Abstract
Background: Blended cognitive behaviour therapy (bCBT) is an effective treatment for fear of cancer recurrence
(FCR) in curatively-treated breast, colorectal and prostate cancer survivors with high FCR. However, long-term
outcomes are unknown. This study investigated the long-term efficacy and cost-effectiveness of bCBT compared
with care as usual (CAU).
Methods: Eighty-eight cancer survivors with high FCR (Cancer Worry Scale ≥14) were randomly assigned to bCBT
(n = 45) or CAU (n = 43). Data were collected at baseline and at three, nine and fifteen months from baseline and
analysed by modified intention-to-treat. Efficacy was investigated with linear mixed-effects models. Cost-
effectiveness was investigated from a societal perspective by comparing costs with quality-adjusted life-years
(QALYs).
Results: Participants who received bCBT reported significantly lower FCR compared with CAU (mean difference of
− 1.787 [95% CI -3.251 to − 0.323, p = 0.017] at 15 months follow-up), and proportionally greater self-rated and
clinically significant improvement at each follow-up measurement. Total QALYs were non-significantly different
between conditions when adjusted for utility score baseline differences (0.984 compared to 0.957, p = 0.385),
while total costs were €631 lower (95% CI -1737 to 2794, p = 0.587). Intervention costs of bCBT were €466. The
incremental cost-effectiveness ratio amounted to an additional €2049 per QALY gained, with a 62% probability that
bCBT is cost-effective at a willingness to pay (WTP) threshold of €20,000 per QALY. Results were confirmed in
sensitivity analyses.
Conclusions: bCBT for cancer survivors with FCR is clinically and statistically more effective than CAU on the
long-term. In addition, bCBT is a relatively inexpensive intervention with similar costs and QALYs as CAU.
Trial registration: The RCT was registered in the Dutch National Trial Register (NTR4423) on 12-Feb-2014.
This abstract was previously presented at the International Psycho-Oncology Society conference of 2018 and
published online. (Psycho-oncology, 27(S3):8-55; 2018)
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Background
Fear of cancer recurrence (FCR), the “fear, worry, or
concern relating to the possibility that cancer will come
back or progress” [1, 2], is highly prevalent amongst can-
cer survivors. Although some degree of FCR is normal
and adaptive, high levels are associated with reduced
quality of life, functional impairment, distress, anxiety,
depression, excessive reassurance-seeking and increased
healthcare costs [3–8]. It is estimated that around a
third (31–38%) of Dutch curatively-treated cancer
survivors experience high FCR [3, 9–11]. FCR seems to
be a universal concern of cancer survivors rather than a
cancer type-specific problem, estimates of FCR did not
differ by cancer types [12]. There is consistent evidence
that younger age, presence and severity of physical
symptoms, psychological distress, lower quality of life,
female gender and lower education are associated with
higher FCR [3].
Four randomised controlled trials (RCTs) of
therapist-delivered interventions to help cancer survivors
manage FCR have been published to date [13–16].
Although the theoretical foundations, formats and deliv-
ery methods of these interventions differ, all available
treatments are based on cognitive behaviour therapy
(CBT) and some are delivered online via the internet
(eHealth) [14, 17, 18]. Online CBT is a promising and
potentially cost-effective treatment modality [19–21],
which is at least as effective as face-to-face CBT for
many mental disorders [22–25]. Online CBT may reduce
waiting lists, travel time and costs [26], productivity
losses [20, 26], and improve accessibility [20]. Possible
disadvantages of online therapy include a lack of per-
sonal interaction, poorer adherence and less engagement
[19]. Blended therapy, in which face-to-face and online
therapy are combined, might bridge this gap. The Survi-
vors’ Worries of Recurrent Disease (SWORD) study is a
blended CBT (bCBT) treatment for high FCR. Immedi-
ate post-treatment efficacy has been established in an
RCT which compared bCBT with care as usual (CAU)
in Dutch cancer survivors with high FCR [14]. FCR was
significantly reduced at 3 months follow-up in partici-
pants who received bCBT compared to those who
received CAU (Cancer Worry Scale mean difference of
− 3.48, 95% CI -4.69 to − 2.28, p < 0.001) with a medium
to large effect size (d = 0.76) [14]. More detailed method-
ology and results are reported elsewhere [14, 27]. Effi-
cacy at 6 and 11months post-treatment has been
demonstrated for two other FCR interventions [13, 16],
however efficacy beyond the first year after treatment
has received little attention. Only one trial to date has
included a follow-up beyond the first year after treat-
ment ended; this study of a therapist-delivered FCR
intervention found that treatment was not more effective
than CAU in reducing FCR at 15 months [15]. No
previous studies have evaluated the cost-effectiveness of
an individual psychological intervention for FCR,
however one study has evaluated the cost-effectiveness
of two group-based interventions to reduce fear of
progression in cancer patients of mixed disease stage
[28]. This study found that group CBT was less costly
than supportive-experiential group therapy with a simi-
lar reduction of fear of progression [28].
With increasingly constrained healthcare budgets it is
important to ensure that the benefits of an intervention
outweigh the costs [29]. Therefore, this study aimed to
evaluate the efficacy and cost-effectiveness of the
SWORD intervention at 9 and 15months follow-up.
Methods
Study design and participants
Detailed information concerning study design, recruit-
ment and inclusion/exclusion criteria is published
elsewhere [27]. Between 2014 and 2016, a multicentre
prospective two-arm RCT was conducted investigating
the efficacy of bCBT in cancer survivors with high FCR
(Cancer Worry Scale score ≥ 14). In total, 88
curatively-treated breast (BC), prostate (PC) and
colorectal cancer (CRC) survivors who had completed
primary medical treatment at least six months and no
longer than five years were included. Eligible participants
who gave informed consent were randomly assigned to
receive either CAU or bCBT. The RCT was approved by
an ethical board (CMO Arnhem-Nijmegen), registered
in the Dutch National Trial Register (NTR4423) and
adheres to CONSORT guidelines.
Intervention and care as usual
The intervention was delivered as blended care during a
3-month period: five individual one-hour face-to-face
sessions (sessions 1, 2, 3, 5, 8) combined with three
15-min e-consultations (chat application, sessions 4, 6,
7) and access to a website. Therapeutic techniques
applied in the intervention included psycho-education,
cognitive restructuring, and behavioral modification.
One face-to-face booster session followed at three
months post-therapy. Participants who received CAU
had no restrictions regarding the use of other psycho-
social support during the study period.
The website was developed in agreement with Dutch
privacy laws equal to HIPAA. All communication from
and to their servers was encrypted. The hosting network
was certified.
Outcome measures
Questionnaires were completed before randomization
(baseline, T0), and at three months (T1), nine months
(T2) and fifteen months (T3) after baseline assessment.
The primary outcome measure was FCR, assessed with
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the Cancer Worry Scale (CWS). The CWS is a reliable
and valid questionnaire which measures FCR on an
8-item 4-level scale [10]. Total scores range between 8
and 32 and a cut-off score of ≤13 versus ≥14 differenti-
ates between low and high FCR [10]. Secondary
outcomes were FCR severity (Fear of Cancer
Recurrence Inventory [FCRI] severity subscale) [30],
cancer-specific distress (Impact of Events Scale [IES])
[31, 32], distress (Hospital Anxiety and Depression
Scale [HADS]) [33], fatigue (Checklist Individual
Strength 8R [CIS-8R]) [34], and health-related quality
of life (HRQoL; European Organisation for Research
and Treatment of Cancer Quality of Life Question-
naire C30 [EORTC QLQ-C30]) [35].
Costs and quality-adjusted life years (QALYs) were
used as the outcome measures in the cost-effectiveness
analyses. The QALY combines quality (weighed by utility
scores) and quantity of life (life years gained) in one
measure and is the predominant outcome measure used
in health economic evaluations to assess value for
money of interventions. QALYs enable comparison of
cost-effectiveness of different interventions across differ-
ent disease areas. Each QALY gained is worth a certain
maximum monetary value that governmental organiza-
tions or insurance companies are willing to pay; also
called willingness to pay (WTP) thresholds. To calculate
QALYs, utility scores were obtained by using the
EuroQol five dimensions three-level questionnaire
(EQ-5D-3 L) and by applying the Dutch EQ-5D tariff
[36, 37]. Utility scores are preference-based quality of life
values, generally ranging from 0 (death) to 1 (perfect
health). These utilities were multiplied by the duration
of follow-up (fifteen months) to calculate QALYs.
The economic evaluation was conducted from a so-
cietal perspective, and therefore included medical
costs (healthcare resource use and medication),
non-medical costs (informal care and loss of product-
ivity from paid work) and costs of the bCBT inter-
vention. Both medical- and non-medical resource use
were measured by pre-defined self-reported cost diar-
ies collected at T1, T2 and T3. Resource use volumes
were valued using standard Dutch reference prices for
2014 if available (Additional file 1: Appendix 1) [29].
The economic impact of absence from paid work was
calculated using the friction cost method [38], which
was set at 12 weeks in 2014 in the Netherlands [29].
Intervention program costs included bottom-up calcu-
lated costs of psychologist training, supervision and
consultations, in addition to costs of website develop-
ment, updates and user licences divided by a conser-
vative amount of potential annual users in a regional
implementation scenario (Additional file 1: Appendix
2) [39, 40]. No costs or effects were discounted due
to the short study period.
Statistical analysis
For the analysis of the primary outcome of FCR, all
secondary outcomes and health-economic outcomes, a
modified intention-to-treat (mITT) analysis was
performed; in which participants who experienced a
recurrence of cancer during the follow-up period were
retained in the analysis, but only their scores before
recurrence were included in the analysis.
Clinical outcomes
Long-term effects of bCBT on primary and secondary
outcomes were examined by fitting a linear mixed-effects
model for mean CWS follow-up scores. This model in-
cluded treatment condition, follow-up time (using discrete
time points) and their interaction, with an unstructured
residual-error covariance matrix specified to account for
the within-person correlation on the repeated follow-up
measures. Baseline score and primary cancer type were in-
cluded as covariates. The latter was a stratification variable
for randomisation and was also found to be associated
with the probability of missing data at T2 and T3. For the
primary outcome of FCR, two sensitivity analyses were
conducted. In the first sensitivity analysis, participants
who reported a recurrence were excluded from the
analysis dataset. The second sensitivity analysis was a per
protocol analysis of participants who completed the bCBT
intervention (intervention arm) and who had full
follow-up data on FCR. All analyses for the clinical
outcomes were conducted in Stata 14.2.
Clinically significant improvement (CSI) on levels of
FCR between baseline and both T2 and T3 follow-up
assessments was established by combining statistically
reliable improvement (reliable change index < 1.96) [41]
and a decrease of CWS scores to the normal range
(clinically significant change, CWS < 14) [27]. Self-rated
improvement had occurred if the participant answered
‘yes’ to ‘feeling much better but still experiencing some
FCR’ or ‘no longer experiencing FCR’.
Health economic outcomes
Missing total cost and utility score data per measure-
ment were imputed at the aggregated level separately
per treatment arm, by using multiple imputation (MI)
by chained equations with predictive mean-matching
[42, 43]. Twenty imputed datasets were created and
pooled according to Rubin’s rules [44].
First of all, incremental costs and incremental QALYs
between the CAU and bCBT strategies were calculated
and statistical differences in non-normally distributed
costs and QALYs were tested with bootstrapped t-tests
[45]. Non-parametric percentile bootstrapping with 1000
replications was performed to estimate 95% confidence in-
tervals [46]. In order to weigh incremental costs against
incremental QALYs, the incremental cost-effectiveness
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ratio (ICER) was calculated by dividing total incremental
costs by the incremental QALYs to obtain the costs per
QALY gained by the intervention [39]. Due to sub-
stantial differences in EQ-5D baseline utility scores
between conditions, regression-based adjustment was
performed within the net monetary benefit frame-
work, which values both benefits and costs in monet-
ary terms and therefore enables the use of regression
methods [47]. Incremental net monetary benefit
(INMB) statistics were estimated for different WTP
thresholds. The INMB was calculated by using the
following formula: (incremental QALY * WTP) – in-
cremental costs. Cost-effectiveness acceptability curves
(CEACs) were constructed which display the probabil-
ity that bCBT would be cost-effective given specific
WTP thresholds [48]. A sensitivity analysis was
conducted which used condition-specific utility scores
calculated from the EORTC QLQ-C30 instead of
utility scores calculated from the EQ-5D-3 L [49].
Results
Sample characteristics
In total, 45 participants were randomly assigned to
bCBT and 43 to CAU (Fig. 1). Both conditions were
comparable on demographic characteristics and clinical
characteristics (Table 1). Nine participants reported a
recurrence at some point during follow-up (bCBT: 8,
CAU: 1) and one participant receiving CAU reported a
new primary cancer. Three of these patients dropped
out of the study (bCBT: 2, CAU: 1). Furthermore, 16
participants dropped out of the study during follow-up
for various other reasons (bCBT: 5, CAU: 11; Fig. 1).
Having had colorectal cancer (p = 0.047) and having co-
morbid conditions (p = 0.044) was significantly associ-
ated with dropout at any stage during the study. The
number of completers (who completed all CWS ques-
tionnaires and, for bCBT, the full intervention) was 23 in
the bCBT and 30 in the CAU condition.
Clinical outcomes
Results for the primary and secondary clinical outcomes
are presented in Table 2. The decrease in FCR was
significantly greater in participants who received bCBT
compared with CAU at all follow-up measurements
(Additional file 1: Appendix 3). At T3, the detected
mean difference in FCR remained statistically significant
(− 1.787, 95% CI -3.251 to − 0.323, p = 0.017), although
smaller than at T1 (− 3.534, 95% CI -4.764 to − 2.305,
p = 0.000) and T2 (− 4.104, 95% CI -5.531 to − 2.677,
p = 0.000). Similar results were found in the per
protocol sensitivity analysis. In the sensitivity analysis
which excluded participants with recurrences, the
reduction in FCR in the bCBT condition was larger at
each follow-up measurement than in the primary
analysis (Additional file 1: Appendix 4).
Regarding the secondary outcomes, participants re-
ceiving bCBT experienced significantly greater improve-
ment at each follow-up measurement on anxiety,
emotional functioning and the FCRI severity subscale
compared with CAU. Significant improvement at T1 and
T2 was found on distress, depression and global quality
of life. On the other six secondary outcomes (cancer--
specific distress, fatigue and physical, role, social and
cognitive functioning), a statistically significant effect
was found at T1.
Significantly more participants receiving bCBT
compared with CAU reported reliable improvement
(78% vs. 19%, p ≤ 0.001), clinically significant change
(58% vs. 9%, p ≤ 0.001), clinically significant improve-
ment (51% vs. 3%, p ≤ 0.001) and self-rated improvement
(74% vs. 41%, p = 0.007) at T2. At T3, only clinically sig-
nificant change (50% vs. 16%, p = 0.038) and self-rated
improvement (72% vs. 40%, p = 0.020) remained signifi-
cantly higher in bCBT (Additional file 1: Appendix 5).
Health economic outcomes
Participants receiving bCBT reported substantially lower
costs on most medical resource categories, including
medical specialists, psychosocial help and diagnostics
(Additional file 1: Appendix 6). Costs of the bCBT inter-
vention programme amounted to €466 (Additional file 1:
Appendix 2), which were added to the costs made by
bCBT participants. Total costs (combined medical,
non-medical and bCBT intervention costs) over the
complete follow-up period were non-significantly
lower in those who received bCBT compared with
CAU (− €164, 95% CI -2018 to 2502, p = 0.891).
Results of the different cost-effectiveness analyses are
shown in Table 3. Baseline EQ-5D utility scores were sub-
stantially higher in the bCBT condition (0.78 [SD = 0.18])
than in CAU (0.68 [SD = 0.22]) (Additional file 1: Appendix
3). Mean QALYs unadjusted for this baseline difference
were significantly higher in the bCBT condition (1.027
compared to 0.913, p = 0.018). However, QALYs were
non-significantly different when these were adjusted for
baseline EQ-5D utility scores (0.984 compared to 0.957, p
= 0.385) and when QALYs were calculated from QLQ-C30
utility scores (1.107 compared to 1.074, p = 0.137).
Since the total costs were lower and total QALYs were
higher when QALYs were unadjusted for baseline utility
differences, bCBT was the dominant strategy (negative
ICER) in this analysis. The same applies to the analysis
which used QALYs calculated from QLQ-C30 utility
scores instead of EQ-5D utility scores. An ICER
of €2049 per QALY gained was found when QALYs were
adjusted for baseline EQ-5D utility differences, since
bCBT was both less costly and less effective in this
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Fig. 1 CONSORT flow diagram showing recruitment and enrolment of 88 participants. Participants who reported a recurrence, but still filled in
questionnaires while they had a recurrence (6 additional patients in the bCBT group), are not listed as ‘lost to follow up’. Abbreviations: bCBT,
blended cognitive behaviour therapy; CAU, care as usual; BC, breast cancer; CRC, colorectal cancer; PC, prostate cancer; CWS, cancer worry scale;
EQ-5D, EuroQol five dimensions questionnaire
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analysis. INMBs in the unadjusted and QLQ-C30 ana-
lyses were in favour of the bCBT condition regardless of
society’s WTP per QALY gained, while adjusted INMBs
were in favour of bCBT above a WTP of €2049 per
QALY gained (which is equal to the ICER). However, all
INMBs had wide confidence intervals, most of which in-
cluded 0 at all WTP values. The CEAC shows that there
is a 48 to 56% probability that bCBT is cost-saving
compared to CAU, and a 62 to 95% probability that
bCBT is more cost-effective than CAU at a WTP of
€20,000 (Fig. 2). This probability obviously increases as
WTP values increase.
Discussion
This study investigated the long-term efficacy and
cost-effectiveness of bCBT to reduce FCR in PC, BC
and CRC survivors with high FCR. It was shown previ-
ously that bCBT resulted in a statistically and clinically
significant reduction of FCR severity immediately post-
treatment (3 months) compared with CAU [14]. The
current study found that the effect of bCBT remained
significant during follow-up at 9 and 15 months [50].
Findings were confirmed in the sensitivity analyses.
Furthermore, more bCBT than CAU participants re-
ported self-rated improvement and clinically significant
improvement at 9 and 15 months. However, the
difference in clinically significant improvement at T3
was not statistically significant, reflecting the finding
that FCR increased slightly in the bCBT condition and
significantly decreased in the CAU condition between 9
and 15 months from baseline. The decrease in FCR over
time in the CAU condition is inconsistent with previous
literature reviews stating that high FCR remains stable
over time without intervention [3, 5, 51, 52]. However,
CAU participants received considerably more add-
itional psychosocial support (by either a psychologist,
mental health nurse, social worker or psychiatrist)
than bCBT participants which may explain this de-
crease. For secondary outcomes, those receiving bCBT
improved significantly on multidimensional aspects of
FCR, anxiety and emotional functioning at each
follow-up measurement. Other secondary outcomes
(distress, depression, global quality of life) improved
at T1 and T2, while the remainder (cancer-specific
distress, fatigue and physical, role, social and cognitive
functioning) only improved at 3 months follow-up.
In the economic evaluation, total costs were found
to be numerically but not significantly lower in the
bCBT condition. Intervention costs were relatively
low when calculated for a conservative annual num-
ber of potential users. The amount of additional
QALYs was small and not statistically significant
when adjusted for baseline EQ-5D utility scores and
in the sensitivity analysis using QLQ-C30 utility
scores. All cost-effectiveness analyses resulted in low
costs of bCBT per QALY gained and relatively high
probabilities that bCBT is cost-saving compared to
CAU. The maximum WTP for an additional QALY
in the Netherlands is dependent on the burden of
disease of the addressed condition, ranging from
€20,000 to €80,000 [53]. As the disease burden of
high FCR is not yet reported, we decided to use the
Table 1 Demographic and clinical characteristics at baseline of





Characteristic n (%) n (%)
Age
Mean (SD) 58.0 (11.3) 59.7 (10.0)
Gender
Male 21 (46.7%) 20 (46.5%)
Education
Low (ISCED 0–2) 11 (24.4%) 18 (41.9%)
Middle (ISCED 3–5) 19 (42.2%) 10 (23.3%)
High (ISCED 6–8) 15 (33.3%) 15 (34.9%)
Employment status
Paid Employment 17 (37.8%) 17 (39.5%)
Unemployed 8 (17.8%) 5 (11.6%)
Voluntary work 4 (8.9%) 8 (18.6%)
Retired 16 (35.6%) 14 (32.6%)
Primary cancer site
Breast 18 (40.0%) 18 (41.9%)
Colorectal 12 (26.7%) 10 (23.3%)
Prostate 15 (33.3%) 15 (34.9%)
Treatment type
Surgery 18 (40.0%) 11 (25.6%)
Radiotherapy 0 (0.0%) 3 (7.0%)
Surgery + Radiotherapy 9 (20.0%) 9 (20.9%)
Surgery + Chemotherapy 12 (26.7%) 9 (20.9%)
Surgery + Radiotherapy + Chemotherapy 6 (13.3%) 11 (25.6%)
Time since diagnosis (years)
Mean (SD) 2.4 (1.5) 2.8 (1.3)
Time since last treatment (years)
Mean (SD) 1.9 (1.5) 2.1 (1.4)
Number of comorbid diseases
0 19 (42.2%) 14 (32.6%)
1–2 19 (42.2%) 22 (51.2%)
3+ 7 (15.6%) 7 (16.3%)
Psychological help in the past
yes 22 (50.0%) 26 (60.5%)
Abbreviations: bCBT blended cognitive behaviour therapy, CAU care as usual,
ISCED International Standard Classification of Education, SD standard deviation
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Table 2 Effect of treatment (modified intention-to-treat) on primary and secondary outcomes (n = 88)
bCBT (n = 45) CAU (n = 43)
Mean SE/SD* Mean SE/SD* Mean difference 95% CI p value
Primary outcome
FCR (CWS)
T0 19.622 3.737 19.558 3.744
T1 unadjusted 14.814 4.579 18.487 3.986
T1 adjusted 14.743 0.432 18.277 0.454 −3.534 −4.764 to −2.305 0.000
T2 unadjusted 13.718 4.472 17.844 3.836
T2 adjusted 13.916 0.493 18.020 0.534 −4.104 −5.531 to − 2.677 0.000
T3 unadjusted 14.684 4.539 16.516 4.081
T3 adjusted 14.783 0.504 16.570 0.549 −1.787 −3.251 to −0.323 0.017
Secondary outcomes
Multidimensional aspects of FCR
Severity (FCRI)
T0 21.909 4.850 23.116 6.456
T1 unadjusted 16.605 7.251 22.282 5.991
T1 adjusted 16.989 0.756 21.330 0.788 −4.341 −6.497 to −2.185 0.000
T2 unadjusted 15.025 6.897 21.313 5.171
T2 adjusted 15.957 0.688 20.462 0.742 −4.505 −6.513 to −2.497 0.000
T3 unadjusted 15.842 7.343 19.733 5.539
T3 adjusted 16.599 0.805 19.023 0.879 −2.423 −4.785 to −0.062 0.044
Distress, depression, anxiety
Distress (HADS)
T0 14.089 7.836 15.209 8.911
T1 unadjusted 9.951 8.402 17.131 9.519
T1 adjusted 10.749 0.731 16.003 0.763 −5.254 −7.334 to −3.174 0.000
T2 unadjusted 9.718 7.412 15.862 9.771
T2 adjusted 11.139 0.806 14.897 0.898 −3.759 −6.134 to −1.383 0.002
T3 unadjusted 9.778 8.292 14.889 9.390
T3 adjusted 11.414 0.966 13.228 1.082 −1.813 −4.669 to 1.043 0.213
Anxiety (HADS)
T0 8.156 4.101 8.395 4.914
T1 unadjusted 5.317 4.239 9.447 5.012
T1 adjusted 5.639 0.437 8.951 0.456 −3.312 −4.555 to −2.068 0.000
T2 unadjusted 5.333 4.132 8.862 5.585
T2 adjusted 6.030 0.528 8.549 0.588 −2.519 −4.074 to −0.964 0.002
T3 unadjusted 4.944 4.056 8.333 4.844
T3 adjusted 5.751 0.570 7.734 0.638 −1.984 −3.667 to − 0.301 0.021
Depression (HADS)
T0 5.933 4.218 6.814 4.722
T1 unadjusted 4.634 4.598 7.684 5.152
T1 adjusted 5.050 0.424 7.131 0.442 −2.081 −3.286 to −0.876 0.001
T2 unadjusted 4.385 4.017 7.000 4.751
T2 adjusted 5.042 0.418 6.406 0.467 −1.363 −2.597 to −0.130 0.030
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Table 2 Effect of treatment (modified intention-to-treat) on primary and secondary outcomes (n = 88) (Continued)
bCBT (n = 45) CAU (n = 43)
Mean SE/SD* Mean SE/SD* Mean difference 95% CI p value
T3 unadjusted 4.833 4.675 6.556 4.956
T3 adjusted 5.582 0.504 5.611 0.565 −.029 −1.520 to 1.462 0.970
Cancer-specific distress (IES)
T0 23.044 14.555 24.902 15.604
T1 unadjusted 14.732 14.998 26.026 17.747
T1 adjusted 15.539 2.064 24.598 2.208 −9.059 −15.003 to −3.115 0.003
T2 unadjusted 9.973 13.710 16.643 15.905
T2 adjusted 11.127 2.085 17.107 2.391 −5.979 −12.215 to 0.256 0.060
T3 unadjusted 14.944 14.633 18.259 15.294
T3 adjusted 15.781 2.147 17.254 2.450 −1.473 −7.883 to 4.938 0.653
Fatigue (CIS-8R)
T0 30.222 12.951 36.116 12.585
T1 unadjusted 25.250 11.535 36.684 13.001
T1 adjusted 27.961 1.137 33.478 1.176 −5.516 −8.771 to −2.262 0.001
T2 unadjusted 26.769 11.855 32.586 12.290
T2 adjusted 28.694 1.297 30.512 1.444 −1.818 −5.658 to 2.022 0.353
T3 unadjusted 26.806 11.436 30.556 13.042
T3 adjusted 29.387 1.350 26.888 1.514 2.499 −1.522 to 6.521 0.223
Quality of life (EORTC QLQ-C30)
Global quality of life
T0 62.222 19.672 61.434 20.252
T1 unadjusted 73.062 19.402 57.479 20.483
T1 adjusted 72.504 2.556 58.075 2.682 14.429 7.153 to 21.705 0.000
T2 unadjusted 72.083 21.229 62.500 21.792
T2 adjusted 71.918 3.004 62.632 3.264 9.286 0.576 to 17.997 0.037
T3 unadjusted 73.026 19.609 65.278 19.948
T3 adjusted 72.672 2.823 67.742 3.108 4.930 −3.331 to 13.192 0.242
Physical functioning
T0 87.704 13.406 83.953 16.269
T1 unadjusted 89.380 11.735 80.855 20.010
T1 adjusted 87.552 1.527 82.886 1.606 4.666 .296 to 9.037 0.036
T2 unadjusted 88.750 15.148 86.458 14.809
T2 adjusted 86.246 1.737 87.766 1.893 −1.519 −6.583 to 3.545 0.557
T3 unadjusted 89.649 13.924 84.301 14.560
T3 adjusted 87.986 1.592 86.829 1.721 1.156 −3.479 to 5.792 0.625
Role functioning
T0 77.037 26.181 74.806 25.295
T1 unadjusted 85.659 21.076 74.123 23.474
T1 adjusted 84.543 2.963 75.547 3.142 8.996 0.503 to 17.489 0.038
T2 unadjusted 83.750 23.415 82.292 21.972
T2 adjusted 82.766 3.407 82.705 3.742 0.061 −9.887 to 10.008 0.991
T3 unadjusted 89.035 17.013 84.409 23.148
T3 adjusted 87.388 2.777 85.357 3.043 2.031 −6.095 to 10.157 0.624
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most conservative WTP of €20,000; at which the
probability that bCBT is cost effective ranged from
62 to 95%. However, since total costs and QALYs
were not significantly different and the INMBs had
relatively wide confidence intervals which included
zero, it cannot be concluded that bCBT is more
cost-effective than CAU. Instead, it could be con-
cluded that bCBT and CAU are similar in terms of
costs and QALYs. Nonetheless, as costs of eHealth
interventions are partly dependant on the number of
users [54], it is envisaged that when implemented in
routine care, the intervention will probably become
more cost-effective than demonstrated here.
Like other recent RCTs of psychological interventions,
the present study has demonstrated immediate and
medium-term benefits of a CBT-based psychological
intervention for FCR. However, to our knowledge, this is
the first study to demonstrate efficacy and
cost-effectiveness of a psychological intervention for
FCR beyond the first year after treatment. Several
on-going trials of interventions for FCR include
cost-effectiveness outcomes, and it will be interesting to
compare health-economic results [55–57].
Methodological strengths of this study include the
rigorous RCT design and the broad range of different
clinical and health economic outcomes. Both statis-
tical and clinical change was evaluated, and findings
were adjusted for covariates and confirmed by sensi-
tivity analyses. Despite being adequately powered, a
relatively high number of dropouts (18%) and
Table 2 Effect of treatment (modified intention-to-treat) on primary and secondary outcomes (n = 88) (Continued)
bCBT (n = 45) CAU (n = 43)
Mean SE/SD* Mean SE/SD* Mean difference 95% CI p value
Emotional functioning
T0 64.815 22.883 66.860 22.456
T1 unadjusted 81.589 23.185 60.256 29.830
T1 adjusted 81.647 2.934 59.978 3.078 21.669 13.326 to 30.011 0.000
T2 unadjusted 80.208 22.463 61.719 28.544
T2 adjusted 78.959 3.259 60.785 3.540 18.174 8.731 to 27.617 0.000
T3 unadjusted 77.851 23.592 68.548 25.973
T3 adjusted 77.507 2.987 68.668 3.242 8.839 0.179 to 17.499 0.046
Cognitive functioning
T0 72.963 24.692 68.992 25.350
T1 unadjusted 80.620 19.897 62.393 28.541
T1 adjusted 79.977 2.920 64.662 3.071 15.315 6.989 to 23.641 0.000
T2 unadjusted 82.500 19.954 72.917 28.945
T2 adjusted 80.130 3.276 74.990 3.593 5.140 −4.421 to 14.701 0.292
T3 unadjusted 79.386 22.738 68.280 25.587
T3 adjusted 76.994 3.171 71.780 3.442 5.214 −4.013 to 14.441 0.268
Social functioning
T0 80.000 23.192 71.318 24.754
T1 unadjusted 89.922 17.495 76.923 26.384
T1 adjusted 87.868 2.907 79.225 3.055 8.643 0.306 to 16.979 0.042
T2 unadjusted 85.833 22.504 80.208 22.175
T2 adjusted 83.302 3.052 81.127 3.310 2.176 −6.727 to 11.078 0.632
T3 unadjusted 88.158 19.723 86.022 19.292
T3 adjusted 85.924 2.556 89.059 2.759 3.135 −10.641 to 4.370 0.413
NOTE. Linear mixed-effects models were used to calculate all p-values. Adjusted means were adjusted for the baseline covariates primary cancer site and baseline
value of the corresponding outcome; unadjusted means were unadjusted for covariates. Boldface type indicates a statistically significant effect for adjusted
means (p < 0.05)
*SEs are reported for adjusted means, SDs for unadjusted means
Abbreviations: bCBT blended cognitive behaviour therapy, CAU care as usual; FCR fear of cancer recurrence, CWS Cancer Worry Scale, FCRI Fear of Cancer
Recurrence Inventory, HADS Hospital Anxiety and Depression Scale, IES Impact of Events Scale, CIS-8R Checklist Individual Strength 8R, EORTC QLQ-C30 European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, SD standard deviation, SE standard error
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Table 3 Results of the different cost-effectiveness analyses
Unadjusted Adjusted QLQ-C30
bCBT CAU bCBT CAU bCBT CAU
Costs Mean 6001 6165 6001 6165 6001 6165
95% CI 4552 to 7664 4657 to 7850 4552 to 7664 4657 to 7850 4552 to 7664 4657 to 7850
Incremental costs Mean −164 −164 −164
95% CI −2018 to 2502 −2018 to 2502 −2018 to 2502
QALYs Mean 1.027 0.913 0.984 0.957 1.107 1.074
95% CI 0.966 to 1.083 0.839 to 0.980 0.941 to 1.028 0.912 to 1.001 1.074 to 1.135 1.046 to 1.100
Incremental QALYs Mean 0.114 0.028 0.033
95% CI 0.026 to 0.206* −0.031 to 0.090 −0.012 to 0.072
ICER €-1081 / QALY €2049 / QALY €-6189 / QALY
INMB at WTP of 0 Mean €164 €-57 €164
95% CI €-2018 to €2502 €-2709 to €2370 €-2081 to 2419
INMB at WTP of €20,000 Mean €2403 €498 €807
95% CI €-893 to €5454 €-2514 to €3269 €-1898 to €3249
INMB at WTP of €50,000 Mean €5761 €1331 €1770
95% CI €386 to €11,274* €-3189 to €5773 €-1322 to €5064
NOTE. Unadjusted and adjusted cost-effectiveness analyses used QALYs calculated from EQ-5D utilities, while the QLQ-C30 analysis used QALYs calculated from
EORTC QLQ-C30 utilities. Estimates in the adjusted cost-effectiveness analysis were adjusted for baseline EQ-5D utility scores. Confidence intervals were obtained
after bootstrapping with 1000 replications
Abbreviations: bCBT blended cognitive behaviour therapy, CAU care as usual, QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire C30, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, WTP willingness to pay, QALY quality adjusted life-year
*Significant difference between the two conditions (p < 0.05)
Fig. 2 Cost-effectiveness acceptability curves of the different cost-effectiveness analyses, showing the probability that the intervention is cost-
effective at different willingness to pay (WTP) thresholds. Abbreviations: bCBT, blended cognitive behaviour therapy; QALY, quality-adjusted life
year; QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30
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participants with recurrence (11%) was observed dur-
ing follow-up. Recurrences were self-reported by par-
ticipants and not systematically investigated in
medical records for privacy reasons. More participants
in the bCBT than in the CAU condition reported a
recurrence, which may have occurred due to higher
follow-up adherence of the intervention group. It is
noteworthy that a number of participants with recur-
rence still completed follow-up questionnaires; how-
ever, their data after recurrence was excluded from
the main analysis since we were only interested in the
efficacy and cost-effectiveness of bCBT in disease-free
cancer survivors. Although it is possible that the
intervention remains suitable for people with recur-
rent disease, the extent to which bCBT translates to
or requires adaptation for patients with advanced dis-
ease remains a question for future research.
A further limitation is that this study was not
powered to detect differences in cost-effectiveness and
therefore these outcomes should be interpreted with
caution. Self-reported cost diaries are considered to
be feasible and valid for collecting cost data [58],
although in the current study it was not possible to
distinguish between routine follow-up consultations
and consultations due to reassurance-seeking behav-
iour related to FCR, which may have influenced
results. Furthermore, baseline cost data, inability to
perform unpaid work, limited job performance while
at work and travel costs were not measured.
Baseline differences on EQ-5D utility scores were
substantial while all other baseline characteristics
were comparable between conditions. These differ-
ences are likely to have occurred by chance, as
randomisation was performed independently by a
computer-generated allocation sequence in the RCT.
However, the EQ-5D has been previously reported to
be less sensitive to changes in psychological
well-being due to dominance of physical health
domains [59]. It is possible that the psychological
well-being item in the EQ-5D (‘anxiety/depression’)
may not be sensitive to the psychological impact of
FCR, as cancer survivors may see FCR as a normal or
rational fear and not consider themselves to be
anxious or depressed. Indeed, a relatively large pro-
portion of participants in both conditions (33% in
CAU and 47% in bCBT) reported no problems with
anxiety or depression at baseline, even though all had
high FCR at inclusion. Therefore, we additionally used
the EORTC QLQ-C30 to calculate QALYs, which may
be more sensitive than the EQ-5D in this population.
This analysis resulted in higher mean QALY values
(as expected) [49], but incremental QALYs were com-
parable to findings in the adjusted EQ-5D analysis;
indicating that those results are robust.
Conclusions
This study demonstrates that bCBT is statistically and
clinically more effective than CAU over the first 15
months post-treatment, and a relatively inexpensive
intervention with similar costs and QALYs as CAU.
However, results should be replicated in larger samples
and in subgroups of the investigated population.
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